Literature DB >> 28057542

An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.

M Jack Borrok1, Neil Mody2, Xiaojun Lu3, Megan L Kuhn3, Herren Wu1, William F Dall'Acqua1, Ping Tsui4.   

Abstract

Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the CH2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of CH2 mutations "TM" (L234F/L235E/P331S) and "YTE" (M252Y/S254T/T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in CH2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C(H)2; Fc-silenced; IgG antibody; benign blocker; biotechnology; calorimetry (DSC); developability; immunology; light scattering (dynamic); pharmacokinetics; protein aggregation; thermal analysis

Mesh:

Substances:

Year:  2017        PMID: 28057542     DOI: 10.1016/j.xphs.2016.12.023

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  16 in total

Review 1.  Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.

Authors:  Hilal Ahmad Parray; Shivangi Shukla; Reshma Perween; Ritika Khatri; Tripti Shrivastava; Vanshika Singh; Praveenkumar Murugavelu; Shubbir Ahmed; Sweety Samal; Chandresh Sharma; Subrata Sinha; Kalpana Luthra; Rajesh Kumar
Journal:  Appl Microbiol Biotechnol       Date:  2021-08-23       Impact factor: 5.560

Review 2.  Current progress in innovative engineered antibodies.

Authors:  William R Strohl
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

3.  Extending human IgG half-life using structure-guided design.

Authors:  Brian J Booth; Boopathy Ramakrishnan; Kristin Narayan; Andrew M Wollacott; Gregory J Babcock; Zachary Shriver; Karthik Viswanathan
Journal:  MAbs       Date:  2018-07-26       Impact factor: 5.857

4.  Subversion of natural killer cell responses by a cytomegalovirus-encoded soluble CD48 decoy receptor.

Authors:  Pablo Martínez-Vicente; Domènec Farré; Carolina Sánchez; Antonio Alcamí; Pablo Engel; Ana Angulo
Journal:  PLoS Pathog       Date:  2019-04-04       Impact factor: 6.823

5.  An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.

Authors:  Chang-Han Lee; Tae Hyun Kang; Ophélie Godon; Makiko Watanabe; George Delidakis; Caitlin M Gillis; Delphine Sterlin; David Hardy; Michel Cogné; Lynn E Macdonald; Andrew J Murphy; Naxin Tu; Jiwon Lee; Jonathan R McDaniel; Emily Makowski; Peter M Tessier; Aaron S Meyer; Pierre Bruhns; George Georgiou
Journal:  Nat Commun       Date:  2019-11-06       Impact factor: 14.919

Review 6.  Boosting therapeutic potency of antibodies by taming Fc domain functions.

Authors:  Tae Hyun Kang; Sang Taek Jung
Journal:  Exp Mol Med       Date:  2019-11-18       Impact factor: 8.718

Review 7.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

Review 8.  Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.

Authors:  Chunpeng Yang; Xinyu Gao; Rui Gong
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

9.  Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Authors:  Tania F Rowley; Shirley J Peters; Mike Aylott; Robert Griffin; Nicola L Davies; Louise J Healy; Rona M Cutler; Alison Eddleston; Thomas L Pither; Joshua M Sopp; Oliver Zaccheo; Gianluca Fossati; Katharine Cain; Andrew M Ventom; Hanna Hailu; Eleanor J Ward; John Sherington; Frank R Brennan; Farnaz Fallah-Arani; David P Humphreys
Journal:  Commun Biol       Date:  2018-09-14

10.  An in vivo platform to select and evolve aggregation-resistant proteins.

Authors:  Jessica S Ebo; Janet C Saunders; Paul W A Devine; Alice M Gordon; Amy S Warwick; Bob Schiffrin; Stacey E Chin; Elizabeth England; James D Button; Christopher Lloyd; Nicholas J Bond; Alison E Ashcroft; Sheena E Radford; David C Lowe; David J Brockwell
Journal:  Nat Commun       Date:  2020-04-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.